PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy |
| |
| Authors: | Anne-Marit Sponaas Neda Nejati Moharrami Emadoldin Feyzi Therese Standal Even Holth Rustad Anders Waage Anders Sundan |
| |
| Affiliation: | 1 KG Jebsen Centre for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ; 2 CEMIR, Centre of Molecular Immune Regulation, Norwegian University of Science and Technology, Trondheim, Norway, ; 3 Department of Hematology, St.Olavs University Hospital, Trondheim, Norway, ; University Medical Center of the Johannes Gutenberg University of Mainz, GERMANY, |
| |
| Abstract: | In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore determined PDL1 and PDL2 expression on DC populations in bone marrow of patients with plasma cell disorders using multicolour Flow Cytometry. We specifically looked at CD141+ and CD141- myeloid and CD303+ plasmacytoid DC. The majority of plasma cells (PC) and DC subpopulations expressed PDL1, but the proportion of positive PDL1+ cells varied among patients. A correlation between the proportion of PDL1+ PC and CD141+ mDC was found, suggesting both cell types could down-regulate the anti-tumor T cell response. |
| |
| Keywords: | |
|
|
